Partnering Deals and Alliances with Big Pharma

Partnering Deals and Alliances with Big Pharma

The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

•Detailed partnering activity profiles for each of the top 50 big pharma companies

•Over 300 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners

•Partnering therapy focus revealed

•Partnering activity since 2005 – number of deals per year

•Full listing of partnering deals

•Activity by deal type

•Activity by industry sector

•Activity by phase of development

•Activity by technology type

•Activity by therapeutic area

•Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available

•Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents

•Understand the key deal terms the company has agreed in previous deals

•Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

This premier report provides all the information you require to better understand big pharma partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big pharma companies dealmaking trends over the last four years.

This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big pharma companies based on 2011 pharmaceutical revenues and dealmaking activity since 2005.

Chapter 3 reviews the top deals of 2005-2013 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big pharma company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, industry sector, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

•Detailed partnering activity profiles for each of the top 50 big pharma companies

•Over 300 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners

•Partnering therapy focus revealed

•Partnering activity since 2005 – number of deals per year

•Full listing of partnering deals

•Activity by deal type

•Activity by industry sector

•Activity by phase of development

•Activity by technology type

•Activity by therapeutic area

•Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available

•Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents

•Understand the key deal terms the company has agreed in previous deals

•Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Deals and Alliances with Big Pharma is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big pharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s partnering.

Partnering Deals and Alliances with Big Pharma includes:

•Detailed company profiles for each of the top 50 big pharma companies, including:

•Partnering interests and indications

•Partnering activity since 2005

•Partner companies since 2005

•Partnering activity since 2005 by:

•Partner company

•Deal type

•Industry sector

•Stage of development

•Technology type

•Therapy area

•Over 300 charts showing the dealmaking activity of each company since 2005

•The tools to enable effective and efficient preparation for partnering negotiation with big pharma

•3,000 partnering deals as recorded at Current Agreement, together with contract documents if available

•The leading M&A and partnering deals by value 2005-2012

The Partnering Deals and Alliances with Big Pharma report also provides comprehensive access to available contract documents for each of the fifty big pharma companies.

Analyzing actual company agreements allows assessment of the following:

•What is actually granted by the agreement to the partner company?

•What exclusivity is granted?

•What is the payment structure for the deal?

•How are sales and payments audited?

•What is the deal term?

•How are the key terms of the agreement defined?

•How are IPRs handled and owned?

•Who is responsible for commercialization?

•Who is responsible for development, supply, and manufacture?

•How is confidentiality and publication managed?

•How are disputes to be resolved?

•Under what conditions can the deal be terminated?

•What happens when there is a change of ownership?

•What sublicensing and subscontracting provisions have been agreed?

•Which boilerplate clauses does the company insist upon?

•Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

•Which jurisdiction does the company insist upon for agreement law?

To purchase and know more about this market research reports please visit:  Partnering Deals and Alliances with Big Pharma